The Clinical Efficacy Of Bevacizumab Combined With Chemotherapy In Lung Treatment Of Advanced Non-small Cell Cancer

The incidence of lung cancer increased in recent years,especially non-small cell lung cancer of which most patients in the disease diagnosis has been in the late,unfortunately with poor clinical efficacy.The current efficacy of chemotherapy has reached the bottleneck state.Studies have shown that vascular endothelial growth factor is the main mediator of various factors in the process of vascular dysplasia.As an anti-angiogenesis drug,bevacizumab can bind to human vascular endothelial growth factor,inhibit the formation of neovascularization by blocking its biological activity,and block the nutritional supply of tumor cells,thus inhibiting the proliferation of tumor cells.It is the first anti-angiogenesis drug approved by the Food and Drug Administration for first-line treatment of advanced non-small cell lung cancer.Many studies have confirmed that bevacizumab combined with chemotherapy can effectively prolong the survival of patients with advanced non-small cell lung cancer.Therefore,the application value of bevacizumab in clinical practice deserves further exploration and analysis.Objective:The aim of this study was to observe the efficacy and safety of bevacizumab combined with chemotherapy for advanced non-small cell lung cancer,and to analyze the related factors that may affect the efficacy.Methods:We retrospectively analyzed 29 patients with non-small cell lung cancer treated in Department of Oncology,First Affiliated Hospital of Suzhou University from January 2016 to December 2018.All patients were diagnosed as squamous cell carcinoma or adenocarcinoma by pathology or cell acupuncture.The clinical stage was ?.All patients were not treated with bevacizumab before receiving bevacizumab combined with chemotherapy.The chemotherapy regimen was selected according to the specific conditions of the patients.The therapeutic effect and adverse reactions in the course of treatment were observed and followed up.Drug efficacy was evaluated by a new criterion for evaluating the efficacy of solid tumors.Adverse reactions were graded according to the general toxicity criteria of the National Cancer Institute of the United States.The clinical data were analyzed by sex,age,pathological type and ECOG score,etc.SPSS20.0 statistical software was used for statistical analysis,Fisher precise probability method was used for drug efficacy analysis,Kaplan-Meier method was used for survival time evaluation,log-rank test was used to compare survival curves,P<0.05 was the difference with statistical significance.Results:All patients were able to evaluate the efficacy and toxicity.In 29 patients,8 patients(27.6%)had partial response,16(55.2%)had stable disease and 5(17.2%)had progressive disease.The objective response rate(ORR)was 27.6%,and the disease control rate(DCR)was 82.8%.The median PFS was 4.9 months and the median OS was 12.5 months.The most common adverse reactions related to chemotherapy include bone marrow suppression,nausea and vomiting,liver and kidney dysfunction,most of which are grade I-II,which can be alleviated after symptomatic supportive treatment.The main adverse reactions related to bevacizumab were hemorrhage,thrombus,proteinuria and hypertension.There were no severe adverse events such as shock,heart failure,and no clinical death related to medication.Conclusion:Bevacizumab combined with chemotherapy has beneficial clinical efficacy in the treatment of advanced non-small cell lung cancer,and has advantageous performance in ORR,DCR,PFS,OS and so on.Bevacizumab is well tolerated,and combined chemotherapy has high safety.